- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.11. | ImageneBio: Wedbush startet Coverage mit negativem Votum und Kursziel 2 US-Dollar | 2 | Investing.com Deutsch | ||
| 25.11. | Wedbush assumes coverage of ImageneBio stock with Underperform rating | 2 | Investing.com | ||
| 19.11. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | ImageneBio, Inc. GAAP EPS of -$2.91 | 1 | Seeking Alpha | ||
| 12.11. | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11. | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 387 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 12.11. | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 22.10. | ImageneBio ernennt CEO Kristin Yarema zur Interims-Finanzchefin | 2 | Investing.com Deutsch | ||
| 22.10. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | ImageneBio files to sell 2.51M shares of common stock for holders | 2 | Seeking Alpha | ||
| 08.09. | ImageneBio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.08. | ImageneBio, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.08. | ImageneBio: Vorstand genehmigt Anreizplan 2025 zur Mitarbeitergewinnung | 2 | Investing.com Deutsch | ||
| 01.08. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 143 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 29.07. | ImageneBio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 270 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 24.07. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 23.07. | Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company | 1 | Investing.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,598 | 0,00 % | Evotec Aktie: Kommen Shortseller in Schwierigkeiten? | Lichtblicke bei der Evotec Aktie: In den vergangenen vier Handelstagen hat sich die Biotech-Aktie aus der starken und wichtigen Mehrfach-Supportzone bei 5,06/5,11 Euro absetzen können. Erste Trading-Kaufsignale... ► Artikel lesen | |
| BIOGEN | 156,40 | +0,03 % | Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen | BERLIN/KÖLN (dpa-AFX) - Schlechte Nachrichten für den US-Hersteller Biogen und seinen japanischen Partner Eisai: Ein umfassender Report sieht keinen Beweis für einen Zusatznutzen ihres Alzheimer-Medikaments... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| MAINZ BIOMED | 1,170 | +0,86 % | EQS-News: Mainz BioMed N.V.: DoctorBox nimmt Mainz Biomeds ColoAlert in sein Portfolio auf | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
DoctorBox nimmt Mainz Biomeds ColoAlert in sein Portfolio auf
02.12.2025 / 14:01 CET/CEST
Für den... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,990 | +2,61 % | Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics | ||
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| GALAPAGOS NV | 27,300 | 0,00 % | Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America | Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Pursuant to Belgian... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,800 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,864 | +0,22 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,051 | -1,73 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,970 | 0,00 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| CYTOKINETICS | 57,00 | -0,87 % | Cytokinetics, Incorporated: Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 | Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,570 | +1,77 % | CytomX Therapeutics Inc.: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer | SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,972 | +0,41 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| PERSONALIS | 8,695 | -3,44 % | Personalis, Inc.: Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing | Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate... ► Artikel lesen |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,26 % bei einem Aktienkurs von 6,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.